Covid-19 PD UK [COVID-19]
Research type
Research Study
Full title
Outcome and mortality of hospital admission with COVID-19 for individuals with parkinsonian syndromes
IRAS ID
285686
Contact name
Camille Carroll
Contact email
Sponsor organisation
University of Plymouth
Duration of Study in the UK
0 years, 8 months, 30 days
Research summary
Parkinson’s disease (PD) is the second most common neurodegenerative condition, with an incidence and prevalence that increases with age. The constellation of symptoms experienced in Parkinson’s, such as swallowing difficulties and dementia, potentially increases the risk of poor outcome from Covid-19 infection. In addition, it is likely that people with PD will be older, and have co-morbidities of diabetes and cardiovascular disease. We are interested to learn the outcome of people with Parkinson’s, who test positive with Covid-19 in the hospital setting. In addition we will evaluate whether any Parkinson’s characteristics or patient characteristics appear to be associated with a poor outcome. These data will help identify those patients at highest risk of poor outcome and inform personalised guidance for patients as lockdown is eased. In addition, study data may help refine a vaccination strategy, support planning for ongoing care/rehabilitation needs, as well as applying a risk-stratified approach to resumption of normal care and support services.\n\nWe will invite clinical care teams working in acute care settings to participate in a survey to collect data pertaining to hospital admissions of people with PD who tested positive for Covid-19. The survey will be administered using Jisc on-line, under a licence held by the University of Plymouth. Data is to be collected from the patients’ clinical notes or care record. The study will use a password protected web based data collection form that can be accessed at all participating hospitals.\n
REC name
N/A
REC reference
N/A